Navigation Links
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Date:10/17/2007

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year. "The treatment of small cell lung cancer is extremely challenging, given the limited therapeutic options available," said Mark A. Socinski, Associate Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, and a principal investigator in the Phase 3 study. "Preliminary data suggest that amrubicin could represent a significant improvement in the treatment of small cell lung cancer, for which there have been no major medical advances in more than 20 years."

The study compares amrubicin and topotecan in second-line treatment of SCLC patients with sensitive or refractory disease. Sensitive disease is defined as response to first-line platinum-based therapy, with subsequent progression 90 days or more after completion of therapy. Refractory disease is defined as no objective response or progressive disease within 90 days of completion of therapy. Study participants are randomized in a 2:1 ratio to receive either IV amrubicin (40mg/m2 daily for 3 days) or topotecan (1.5 mg/m2 daily for 5 days), both starti
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
10. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
11. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Ultra Clean Holdings, Inc. (Nasdaq: UCTT ), a ... capital equipment, flat panel, medical, energy and research industries will ... October 24, 2011 after markets close. The Company ... results and management,s outlook at 1:45 pm PDT on Monday, ...
... The medical education landscape has changed dramatically ... pressures have reshaped approaches to Continuing Medical Education ... right staffing, investment, and delivery platforms to provide ... To help inform medical education leaders on ...
Cached Medicine Technology:Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector 2
(Date:7/9/2014)... The liver is one of the most important organs ... that we utilize our food properly this is ... removed from our organism this is its detoxification ... and unhealthy food all damage the liver. The resulting ... deposits, cirrhoses, and life-threatening liver failure. According to the ...
(Date:7/9/2014)... studies linking older age with kidney and heart disease ... donation among older adults. However, in the first study ... Perelman School of Medicine at the University of Pennsylvania ... enjoy similar life expectancy and cardiovascular health as very ... In light of the ever increasing organ transplant waitlists, ...
(Date:7/9/2014)... has risen dramatically in Western societies. One frequently cited ... and have fewer infections than previous generations, thereby delaying ... researchers at Sahlgrenska Academy, University of Gothenburg, monitored children ... the immune system in relation to allergic disease. All ... Vstra Gtaland Region, half of them on farms that ...
(Date:7/8/2014)... awarded up to $15 million by the Defense Advanced ... aiming to help brain-injured people restore lost memory functions. ... psychology and physics will collaborate to create, surgically implant, ... Memory is the process in which neurons in certain ... retrieve it. Certain types of illnesses and injuries disrupt ...
(Date:7/8/2014)... found to be three times higher when auditors were ... auditors present, according to a study in a major ... "Quantification of the Hawthorne effect in hand hygiene compliance ... study," published today on-line in the BMJ Quality ... Srigley, who did the study as part of her ...
Breaking Medicine News(10 mins):Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 2Health News:Health-care worker hand hygiene rates increase three-fold when auditors visible 3
... Schools in the ... Country, ... in association with the School Nutrition,Association and the President,s Council on Physical ... as one,of the 25 healthiest schools in the nation. The recognition is ...
... LAKE CITY, Dec. 11 Amedica Corporation, an,orthopedic ... today that the U.S. Food and Drug Administration,has ... Valeo(TM),ceramic VBR spinal implant., The Valeo VBR ... aid in surgical correction and stabilization of the ...
... red meat and processed meat you eat, the higher the ... hamburger or a small pork chop eaten daily could put ... government health researchers report. , The more red meat ... researchers from the National Cancer Institute concluded. , "Red ...
... Panomics Inc., a,developer of innovative technologies ... the exclusive provider of QuantiGene(R) and,QuantiGene Plex(R) ... today that they have been awarded Frost ... Entrepreneurial Company of the Year,Award. Frost & ...
... YORK, Dec. 10 The holiday season is a ... Combine high-calorie,goodies with the cold winter weather, and December ... Fitness Operations VP at 24 Hour Fitness health,clubs, says ... help stave,off extra "holiday" pounds., Listen to this ...
... REDWOOD CITY, Calif., Dec. 10 Cardica, Inc.,(Nasdaq: ... of the over-allotment,option granted to the underwriters of ... their option to purchase,481,170 shares of common stock ... share., William Blair & Company, L.L.C. acted ...
Cached Medicine News:Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 3Health News:High Meat Consumption Linked to Heightened Cancer Risk 4Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3Health News:Cardica Announces Exercise of Over-Allotment Option 2Health News:Cardica Announces Exercise of Over-Allotment Option 3
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... female urinary stress incontinence (SUI) with a ... (BioArc™ SP) or a transobturator (BioArc™ TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
Medicine Products: